Chenyuan Ventures Closes Its Inaugural RMB 350 Million Fund to Accelerate Early-Stage Innovative Therapeutics and Frontier Biotech

Recently, Chenyuan Venture Capital announced the final closing of its inaugural fund, with a size of RMB 350 million. The investors includeGovernment-guided funds, state-owned asset platforms,Market-oriented fund of funds (FOF) and senior healthcare industry expert.

Chenyuan Venture Capital was established in September 2021 and co-founded by senior investors from China’s biopharmaceutical sector. As a professional firm specializing in incubation and early-stage investment in frontier areas of biopharma, it focuses on innovative drugs, medical devices, biotechnology, and AI-driven healthcare. The firm is committed to identifying and nurturing scientists in cutting-edge fields who possess genuinely original products and technologies. By providing end-to-end industry chain enablement and support, Chenyuan Venture Capital aims to inject new momentum into the development of China’s biopharmaceutical industry and the enhancement of its independent innovation capabilities, while delivering superior returns to its investors.

At the turn of the year, amid a market environment characterized by persistently tepid investor sentiment and ongoing tightening in fundraising conditions, Chenyuan Venture Capital successfully attracted investor attention and trust through its professional team, precise industry insights, and unique investment strategy. Defying the broader trend, the firm completed the first closing of its inaugural fund, demonstrating its professional expertise and resource advantages in the fields of innovative drugs and early-stage frontier technologies.

Gaofeiya, Founding Partner of Chenyuan Venture Capital, graduated from Georgetown University in the United States with a degree in Biopharmaceuticals. She previously engaged in early-stage drug R&D and is well-versed in pharmaceutical development processes. With profound understanding and professional judgment of the biopharmaceutical industries in both China and the United States, she has accumulated extensive industry networks and resources through years of experience in both industry and investment. This enables her to conduct comprehensive project evaluations from multiple industrialization perspectives, including R&D, technology, and market.

The investment team members all possess professional backgrounds in biomedicine and have been deeply engaged in the biomedical sector in both China and the United States for over a decade. They have accumulated extensive experience in industrial investment and M&A, operational management, commercialization, and the translation of scientific research achievements. The total size of funds previously managed, operated, and exited by the team exceeds RMB 3 billion. Through incubating and investing in early-stage R&D projects, the team has collaborated closely with numerous scientists, gaining valuable expertise. Meanwhile, it has established mature models and achieved successful cases in the commercial implementation of innovative technologies.

Chenyuan Venture Capital aims to leverage its global resource network and vision to integrate upstream and downstream industrial chain resources in China and the United States, thereby accelerating the global industrial transformation of original Chinese scientific technologies and products. Meanwhile, the Chenyuan team continuously summarizes and reviews its past early-stage angel investment experience, implements differentiated investment allocations, adopts diversified exit strategies, and fully utilizes its extensive industry expertise and resources to better safeguard the interests of the fund and its investors.

Leveraging the team’s deep industrial resources and experience, Chenyuan Venture Capital has possessed a differentiated investment perspective and advantage in “industrial investment” from its inception.

Chenyuan Venture Capital collaborates with renowned research institutions, universities, and distinguished scientists both in China and abroad to identify cutting-edge global technologies and facilitate their domestic implementation, thereby addressing significant unmet clinical needs. The firm focuses primarily on frontier technologies such as cell therapy, gene therapy, gene editing, and synthetic biology, along with their upstream and downstream industrial chains. Projects incubated from scientists’ laboratories often face a lack of professional management teams; Chenyuan addresses this challenge through deep integration with the industry. Its “autonomous incubation model” involves co-founding biotech companies with scientists and deeply participating in corporate establishment and operational management. This approach allows scientists to concentrate on R&D, leverages individual strengths, ensures efficient company operations, accelerates the transition from scientific research to industrialization, and achieves breakthroughs from “0” to “1.” For early-stage preclinical projects, Chenyuan Venture Capital leverages its industrial resources to rapidly translate laboratory technologies into commercial products and facilitate their market entry globally.

In project selection, Chenyuan Venture Capital places greater emphasis on the originality of underlying technologies and market adaptability. It favors “first-in-class” projects featuring globally leading pioneering innovations and patent protection, with a focus on technological innovativeness, market competitiveness, and robust experimental data. Additionally, the team’s background and global perspective serve as important evaluation criteria, ensuring alignment in philosophy and management approaches between both parties, thereby facilitating post-investment management and industrialization.

China’s large population base and aging trend have generated substantial market demand. Payment-side challenges are merely a temporary pain point in the course of healthcare reform, while the immense potential on the demand side provides a solid foundation for pharmaceutical development. In recent years, as the country has made significant progress in promoting the innovative integration of commercial health insurance with basic medical insurance, Chenyuan Venture Capital believes that a payment solution with Chinese characteristics will be explored in the future, thereby creating broader space for pharmaceutical industry growth.

The current investment landscape for China’s biopharmaceutical industry is complex. On one hand, the domestic pharmaceutical sector is significantly influenced by policy, with national health insurance reimbursement and volume-based procurement (VBP) policies profoundly reshaping the industry structure and corporate operations. Against this backdrop, it is crucial to provide deep, industry-focused empowerment.

“Developing innovative drugs is challenging, and developing original innovative drugs is even more so. Collaboration across the upstream and downstream segments of the industry chain can largely bridge the gap between scientific research and clinical practice, provide portfolio companies with abundant resource support, foster cooperation and synergistic development among enterprises, and thereby accelerate the industrialization of projects,” said Gao Feiya.

Under the planning and assistance of Chenyuan Venture Capital, a certain overseas incubation project of the company has initiated its localization efforts in China. The Chenyuan team has been deeply involved in the preparatory work for its domestic launch, providing comprehensive empowerment in areas including strategic development planning, site selection for offices and manufacturing facilities, team building, talent planning, and linking clinical and industrial resources. In addition to early-stage innovative drug projects, Chenyuan Venture Capital also focuses on enterprises across the pharmaceutical industry chain, aiming to build a more complete industrial ecosystem by investing in upstream and downstream sectors, thereby continuously enhancing and refining its own industrial empowerment capabilities.

Meanwhile, the overseas expansion opportunities for Chinese pharmaceutical companies remain substantial. Through collaborations with multinational pharmaceutical corporations, Chinese innovations have gradually come to the forefront. In the past two years, partnerships between multinational pharmaceutical companies and Chinese innovative drug developers have continued to increase. This is precisely why Chenyuan Venture Capital places significant emphasis on the internationalization of its portfolio projects. By establishing collaborative relationships with multinational corporations (MNCs), leading domestic enterprises, and global clinical CROs, Chenyuan Venture Capital possesses the resources and capabilities to continuously provide its investee companies with opportunities for engagement with MNCs, thereby facilitating their market entry and development on a global scale.

In a complex and ever-changing market environment, Chenyuan Venture Capital has successfully completed the fundraising for its inaugural fund by leveraging its inherent strengths. Looking ahead, we anticipate that Chenyuan Venture Capital will help more Chinese innovations with global competitiveness secure a foothold in the international pharmaceutical market through precise industry insights, an industrial ecosystem featuring upstream and downstream synergy, and deep post-investment value-added services.